Browse treatments

…MMR defects in patients with solid tumours being considered for immunotherapy, use of a validated MSI NGS panel is another option.19 In the e…

…ble clinical outcomes for stage II/III NSCLC patients underwent neoadjuvant immunotherapy. Vβ24-1Jβ2-1 and Vβ29-1Jβ2-7 were mainly localized in non-exhau…

…e also supports the benefit of ICIs in non-metastatic dMMR CRC. Neoadjuvant immunotherapy has produced high rates of pathological response in both colon …

… ~55% disease-free survival (DFS) at 2 years with surveillance. Neoadjuvant immunotherapy induces tumor necrosis and may reduce the risk of local and dis…

…Background Neoadjuvant immunotherapy significantly improves the pathological complete response (pCR)…

…ntially mitigates toxicity without compromising efficacy. Local neoadjuvant immunotherapy may enable more potent immune priming and activation within pre…

…s confirmed metastatic malignant melanoma. The patient received neoadjuvant immunotherapy followed by left thumb amputation and axillary lymph node disse…

…Neoadjuvant immunotherapy has increased rates of pathological complete response (pCR) in …

…ng the current evidence combined with the recent publication of neoadjuvant immunotherapy outcomes in patients with early-stage CRC, these findings justi…

…Background Neoadjuvant immunotherapy has reshaped the treatment paradigm for esophageal squamous cel…

…A potential option for patients who do not have access to neoadjuvant immunotherapy…

…Research on neoadjuvant immunotherapy (NAI) is increasingly focusing on immunotherapy-related adverse…